November 16, 2020
Date: Nov 16, 2020
Duration: 20 Min
Sponsored by Thermo Fisher Scientific
This webcast features: Jeff Johnson, Founder and President, BioTech Design, LLC, Mark Thomas Smith, R&D Engineer, Thermo Fisher Scientific, and Kevin Mullen, Senior Product Manager, Thermo Fisher Scientific
Single-use technologies enable a flexibility and modularity effectively unattainable with more traditional stainless-steel technologies, particularly in upstream bioprocesses. Single-use bioreactors up to 2,000 L are employed largely in preclinical- and clinical-stage bioprocesses to leverage this flexibility. As products reach commercial maturity, scales larger than 2,000 L frequently become desirable to take advantage of economies of scale. With the typical upper limit of single-use bioreactors at 2,000 L, this has traditionally meant transfer to stainless-steel systems.
The introduction of the Thermo Fisher Scientific HyPerforma™ DynaDrive™ 5,000-L bioreactor opens a new paradigm of operation in terms of volume, while providing unprecedented ergonomics and flexibility. In tandem with Thermo Fisher, Jeff Johnson (former head of Merck Single-Use Network) has evaluated the operational and economic implications of this new reactor system and shares his perspective of how the biopharma industry might change with the introduction of the DynaDrive system. Kevin Mullen (Senior Product Manager) introduces the DynaDrive systems, and Mark Thomas Smith (Staff R&D Engineer) explores how this technology can meet the demands of intensifying bioprocesses.
You will learn about:
The introduction of new DynaDrive SUB technology and the associated performance improvements to mass transfer, volume, and scale-up associated therewith
The economics of total facility cost and equivalent cost of goods (cost per gram), including improvements from implementing 5kL single-use bioreactors over 2kL SUBs and larger (≥10kL) stainless-steel vessels
Watch the recorded webcast now.
You May Also Like
